Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
March 13th 2023Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.
Radiotherapy Treatments Are Getting Shorter and Faster in Prostate Cancer
The history of radiation therapy for men with prostate cancer extends back more than a century. From those early crude methods, the field has advanced to delivery potentially curative therapies that can be administered in as little as 2 weeks.
Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUC
March 15th 2022Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.
Immunotherapy and Targeted Treatment Approaches Improve Outcomes in Metastatic Urothelial Cancer
Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.
Frontline mRCC Paradigm Crowds Among Immune-Based Treatment Options
March 13th 2021The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.
Novel Targeted and Immunotherapeutic Agents Reshape Metastatic Urothelial Cancer Landscape
March 12th 2021Treatment options for patients with metastatic urothelial cancer have rapidly expanded as FDA approvals of immunotherapeutics push the boundaries of a once stagnant treatment landscape. Combination regimens and the addition of targeted approaches, further demonstrate progress in areas that have been tough to crack.
Immunotherapy Combinations Are King in Frontline RCC Treatment
In metastatic renal cell carcinoma, the use of frontline combination immunotherapy regimens has led to significant survival benefits for patients, and efforts are now being focused on exploring novel options for those who become refractory to this approach.
Dr. Gomella on the State of Genetic Testing and Screening in Prostate Cancer
March 14th 2020Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the state of genetic testing in prostate cancer.
Dr. Pal on Biomarker Development in Renal Cell Carcinoma
July 15th 2016Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).
Dr. Crawford on Ongoing Research With Radium-223 in mCRPC
July 15th 2016E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses ongoing research with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Dr. Choueiri on Using Immunotherapy to Treat RCC
April 11th 2016Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.
Dr. Gomella on Current Perspectives on Prostate Cancer Screening
April 1st 2016Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of the Kimmel Cancer Center Network, discusses the current perspectives on screening for prostate cancer.
Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways
March 29th 2016Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.